Metrika

  • citati u SCIndeksu: 0
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[]
  • posete u poslednjih 30 dana:4
  • preuzimanja u poslednjih 30 dana:1

Sadržaj

članak: 4 od 316  
Back povratak na rezultate
2020, vol. 148, br. 9-10, str. 613-620
Prevencija venskog tromboembolizma rivaroksabanom i apiksabanom u ortopedskoj hirurgiji
aUniverzitet u Beogradu, Medicinski fakultet + Klinički centar Srbije, Klinika za kardiologiju, Beograd
bUniverzitet u Beogradu, Medicinski fakultet + Srpska akademija nauke i umetnosti (SANU), Beograd
cKlinički centar Srbije, Klinika za kardiologiju, Beograd
dUniverzitet u Beogradu, Medicinski fakultet + Univerzitet u Beogradu, Medicinski fakultet, KBC 'Zemun'
eUniverzitet u Beogradu, Medicinski fakultet + Univerzitet u Beogradu, Medicinski fakultet, Institut za ortopedsko-hirurške bolesti 'Banjica'

e-adresadrantoni@gmail.com
Sažetak
Brojna ograničenja i neželjena dejstva standardnih antikoagulantnih lekova nameću potrebu za primenom novih antikoagulantnih lekova. Peroralni antikoagulantni lekovi iz grupe inhibitora faktora Xa imaju više prednosti, od kojih su najvažnije nepostojanje posebnih ograničenja u ishrani, značajno manji broj interreakcija sa lekovima, rutinska primena bez posebnog laboratorijskog monitoringa, stabilniji i prediktabilniji terapijski efekat. Rivaroksaban, selektivni peroralni inhibitor faktora Xa, efikasniji je od enoksaparina u profilaksi venskog tromboembolizma pri velikim ortopedskim intervencijama. I pored toga što pojedine studije navode da nema razlike u nastanku hemoragijskih komplikacija, određene metaanalize sa rivaroksabanom pokazale su veću učestalost hemoragija. Apiksaban, peroralni reverzibilni inhibitor faktora Xa, pokazao se efikasnijim u prevenciji venskog tromboembolizma u odnosu na evropske doze enoksaparina, a gotovo je podjednako efikasan kao severnoameričke doze. Nisu utvrđene značajnije razlike u stepenu krvarenja, mada studija ADVANCE-I ukazuje na manju učestalost krvarenja kod onih lečenih apiksabanom. Radi razjašnjenja kontradiktornih rezultata u novijim metaanalizama u odnosu na poređenje navedenih inhibitora faktora X i različitih režima komparatora enoksaparina, kao i u odnosu na rizik za simptomatski plućni tromboembolizam i ukupna krvarenja posle velikih ortopedskih operacija, biće neophodna nova istraživanja. Specifičnosti rivaroksabana i apiksabana, koji prema savremenim preporukama već čine sastavni deo protokola profilakse venskog tromboembolizma u velikim ortopedskim intervencijama, omogućiće uspostavljanje personalizovanih protokola kako bi se uspostavio bolji sigurnosni profil kod svakog bolesnika.
Reference
*** (2019) Highlights of prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/202439s029lbl.pdf (accessed 31 December)
*** (2018) Thromboprophylaxis: Orthopedic surgery. http://thrombosiscanada.ca/wp-content (accessed December 2019)
*** Arixtra: EPAR: Product information. www.ema.europa.eu
*** Pradaxa: EPAR: Product information. www.ema.europa.eu
*** (2012) RADAR NPS (Rational Assessment of Drug and Research). http://www.nps.org.au/health_professionals/publications/nps_radar/2012/january_2012
Antonijevic, N.M., Milosevic, R., Perunicic, J., Stanojevic, M., Calija, B., Vasiljevic, Z. (2005) Need for more intensive treatment of patients with acute pulmonary embolism caused by heparin-induced thrombocytopaenia type II. European Heart Journal, 26(24): 2745-2746
Antonijević, N., Stanojević, M., Peruničić, J., Đokić, M.R., Miković, D., Kovač, M., Miljić, P., Milošević, R., Terzić, B., Vasiljević, Z.M. (2004) Heparin induced thrombocytopenia type II and myocardial infarction: Two case reports. Srpski arhiv za celokupno lekarstvo, vol. 132, br. 1-2, str. 33-37
Antonijević, N.M., Radovanović, N., Obradović, S., Vucelić, D., Stojanović, B., Miković, D., Kovač, M., Kočica, T., Tadić, S., Antonijević, I., Drašković, S., Đorđević, V., Čalija, B., Peruničić, J. (2010) Obstacles in the diagnostics and therapy of heparin-induced thrombocytopenia. Srpski arhiv za celokupno lekarstvo, 138(suppl. 1): 69-73
Antonijević, N., Stanojević, M., Milošević, R., Miković, D., Kovač, M., Terzić, B., Vasiljević, Z.M. (2003) Heparin-induced thrombocytopenia type II: Innovations in diagnostics and treatment. Medicinski pregled, vol. 56, br. 5-6, str. 247-250
Antonijević, N.M., Jovanović, L., Đorđević, V., Živković, I., Vukčević, M., Apostolović, M., Kanjuh, V. (2014) Contemporary approach to primary prophylaxis of venous thromboembolism regarding the impact of risk factors on anticoagulation therapy duration. Srpski arhiv za celokupno lekarstvo, vol. 142, br. 3-4, str. 249-256
Antonijević, N., Stanojević, M., Milošević, R., Đorđević, V., Jauković, M., Vukčević, V., Kovač, M., Miković, D., Radojković, D., Vasiljević, Z. (2005) Combined thrombophilic risk factors and essential thrombocythemia in patient with recurrent venous thromboembolic episodes: Thirty-three-year follow-up. Journal of Thrombosis and Thrombolysis, 19(2): 93-95
Bayer plc Summary of product characteristics: Xarelto®. https://www.medicines.org.uk/emc/product/6402/smpc on 20/08/2018 [last updated 18 July 2018]
Bristol-Myers Squibb-Pfizer Summary of Product Characteristics: Eliquis®. https://www.medicines.org.uk/emc/product/4756/smpc on 20/08/2018 [last updated 16 August 2018]
Cao, Y.B., Zhang, J.D., Shen, H., Jiang, Y.Y. (2010) Rivaroxaban versus enoxaparin for thromboprophylaxis after total hip or knee arthroplasty: A meta-analysis of randomized controlled trials. European Journal of Clinical Pharmacology, 66(11): 1099-1108
Cohen, A.T., Spiro, T.E., Büller, H.R., Haskell, L., Hu, D., Hull, R., Mebazaa, A., Merli, G., Schellong, S., Spyropoulos, A.C., Tapson, V. (2013) Rivaroxaban for thromboprophylaxis in acutely ill medical patients. New England Journal of Medicine, 368(6): 513-523
Eikelboom, J.W., Weitz, J.I. (2010) New Anticoagulants. Circulation, 121(13): 1523-1532
Eriksson, B.I., Bauer, K.A., Lassen, M.R., Turpie, A.G., Steering Committee of the Pentasaccharide in Hip-Fracture Surgery Study (2001) Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. New England Journal of Medicine, 345(18): 1298-304
Feng, W., Wu, K., Liu, Z., Kong, G., Deng, Z., Chen, S., Wu, Y., Chen, M., Liu, S., Wang, H. (2015) Oral direct factor Xa inhibitor versus enoxaparin for thromboprophylaxis after hip or knee arthroplasty: Systemic review, traditional meta-analysis, dose-response meta-analysis and network meta-analysis. Thrombosis Research, 136(6): 1133-1144
Fisher, W.D. (2011) Impact of venous thromboembolism on clinical management and therapy after hip and knee arthroplasty. Canadian Journal of Surgery / Journal canadien de chirurgie, 54(5): 344-351
Galliazzo, S., Donadini, M.P., Ageno, W. (2018) Antidotes for the direct oral anticoagulants: What news?. Thrombosis Research, 164(Suppl 1): S119-S123
Goldhaber, S.Z., Leizorovicz, A., Kakkar, A.K., Haas, S.K., Merli, G., Knabb, R.M., Weitz, J.I., ADOPT Trial Investigators (2011) Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. New England Journal of Medicine, 365(23): 2167-2177
Gómez-Outes, A., Terleira-Fernández, A.I., Suárez-Gea, M.L., Vargas-Castrillón, E. (2012) Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: Systematic review, meta-analysis, and indirect treatment comparisons. BMJ, 344: e3675
Gray, E., Mulloy, B., Barrowcliffe, T.W. (2008) Heparin and low-molecular-weight heparin. Thromb Haemost, 99(5):807-18
Hanna, M.S., Mohan, P., Knabb, R., Gupta, E., Frost, C., Lawrence, J.H. (2014) Development of apixaban: A novel anticoagulant for prevention of stroke in patients with atrial fibrillation. Annals of the New York Academy of Sciences, 1329(1): 93-106
Heo, Y. (2018) Andexanet alfa: First global approval. Drugs, 78(10): 1049-1055
Huisman, M.V., Quinlan, D.J., Dahl, O.E., Schulman, S. (2010) Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials. Circ Cardiovasc Qual Outcomes, 3(6): 652-60
Huisman, M.V. (2011) The proof for new oral anticoagulants: Clinical trial evidence. European Orthopaedics and Traumatology, 2(1-2): 7-14
Hull, R. (2009) Oral antithrombotic inhibitors: Dabigatran etexilate, meeting an unmet need?. Clinical and Applied Thrombosis/Hemostasis, 15(Suppl 1): 5S-8S
Hunt, B.J. (2009) The prevention of hospital-acquired venous thromboembolism in the United Kingdom. British Journal of Haematology, 144(5): 642-652
Kearon, C., Akl, E.A., Ornelas, J., Blaivas, A., Jimenez, D., Bounameaux, H., i dr. (2016) Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest, 149(2): 315-52
Kim, S. (2012) Apixabane: A new oral direct Xa infibitor. PharmaNote, 27(4):1-9
Kubitza, D., Becka, M., Zuehlsdorf, M., Mueck, W. (2006) Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects. Journal of Clinical Pharmacology, 46(5): 549-558
Lassen, M.R., Bauer, K.A., Eriksson, B.I., Turpie, A.G.G., Eur Pentasaccharide Elective Surgery Study (EPHESUS) Steering Committee (2002) Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: A randomised double-blind comparison. Lancet, London, 359(9319): 1715-1720, England
Ma, G., Zhang, R., Wu, X., Wang, D., Ying, K. (2015) Direct factor Xa inhibitors (rivaroxaban and apixaban) versus enoxaparin for the prevention of venous thromboembolism after total knee replacement: A meta-analysis of 6 randomized clinical trials. Thrombosis Research, 135(5): 816-822
Misselwitz, F., Berkowitz, S.D., Perzborn, E. (2011) The discovery and development of rivaroxaban. Annals of the New York Academy of Sciences, 1222: 64-75
Mitić-Milikić, M.M., Vukčević, M.D. (2004) Savremeni stavovi u dijagnostici plućne tromboembolije. Vojnosanitetski pregled, vol. 61, br. 2, str. 187-191
National Institute for Health and Clinical Exellence (2018) NICE clinical guideline. London, Issue date March, www.nice.org.uk; 1-43
Sasaki, H., Ishida, K., Shibanuma, N., Tei, K., Tateishi, H., Toda, A., Yamashiro, Y., Matsumoto, T., Kuroda, R., Kurosaka, M. (2014) Retrospective comparison of three thromboprophylaxis agents, edoxaban, fondaparinux, and enoxaparin, for preventing venous thromboembolism in total knee arthroplasty. International Orthopaedics, 38(3): 525-529
Spyropoulos, A.C., Ageno, W., Albers, G.W., Elliott, C. G., Halperin, J.L., Hiatt, W.R., Maynard, G.A., Steg, P. G., Weitz, J.I., Suh, E., Spiro, T.E., Barnathan, E.S., Raskob, G.E. (2018) Rivaroxaban for thromboprophylaxis after hospitalization for medical illness. New England Journal of Medicine, 379(12): 1118-1127
Stevanović, M., Apostolović, M., Stojsavljević, J., Vučković, V., Krneta, O. (1998) Intraoperativne i postoperativne komplikacije pri ugradnji totalne endoproteze kuka. Acta Orthopaedica Iugoslavica, 29(2): 161-4
Thomas, T.F., Ganetsky, V., Spinler, S.A. (2013) Rivaroxaban: An oral factor Xa inhibitor. Clinical Therapeutics, 35(1): 4-27
Ufer, M. (2010) Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development. Thrombosis and Haemostasis, 103(03): 572-585
Winchester, C. (2012) New oral antithrombotics: Focus on dabigatran, an oral, reversible direct thrombin inhibitor for the prevention and treatment of venous and arterial thromboembolic disorders. Vascular Health and Risk Management, 8:45-57
World Health Organization (2012) Guidelines for ATC classification and DDD assignment 2013. http://www.whocc.no/filearchive/publications/1_2013guidelines.pdf
Yu, Z., Shan, P., Yang, X., Lou, X. (2018) Comparison of efficiency and safety of rivaroxaban, apixaban and enoxaparin for thromboprophylaxis after arthroplastic surgery: A meta-analysis. Bioscience Reports, 38(6): BSR20180423
 

O članku

jezik rada: engleski
vrsta rada: prikaz
DOI: 10.2298/SARH200116063A
primljen: 16.01.2020.
prihvaćen: 17.08.2020.
objavljen onlajn: 09.09.2020.
objavljen u SCIndeksu: 13.11.2020.